Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 888

Sort by

Sort Order Select

Journal Articles

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331

Patrick A. Brown, MD, Lingyun Ji, PhD, Xinxin Xu, MS, Meenakshi Devidas, PhD, Laura Hogan, MD, Michael J. Borowitz, MD PhD, Elizabeth A. Raetz, MD, Gerhard Zugmaier, Elad Sharon, MD MPH, Lia Gore, MD, James A. Whitlock, MD, Michael A. Pulsipher, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_2): LBA-1.

https://doi.org/10.1182/blood-2019-132435

Published: 2019

Journal Articles

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Jessica C. Hochberg, MD, Jaclyn Basso, RN, MSN, PNP, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Allyson M. Flower, MD, Aliza Gardenswartz, MD, Qiuhu Shi, PhD, Perry Gerard, MD MBA, FACR, Humayan Islam, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 127.

https://doi.org/10.1182/blood-2019-128684

Published: 2019

Journal Articles

Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen

Blood (2019) 134 (Supplement_1): 463.

https://doi.org/10.1182/blood-2019-127811

Published: 2019

Journal Articles

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b

Jessica K. Altman, Tsila Zuckerman, MD, Olga Frankfurt, MD, Selina M. Luger, MD FRCPC, Dale L. Bixby, MD, Vamsi Kota, MBBS, Micah M. Burch, Ofir Wolach, Itai Levi, MD, Anna Gourevitch, Ron Ram, MD, Liat Flaishon, Shoshi Tessler, Stela Gengrinovitch, Ruth Ben Yakar, Jacob M. Rowe, MB, BS

Blood (2019) 134 (Supplement_1): 179.

https://doi.org/10.1182/blood-2019-124330

Published: 2019

Journal Articles

Pharmacokinetic-Guided Busulfan Based Myeloablative Versus Fixed Dose Reduced Intensity Conditioning Regimen in Patients Older Than 55 Years Undergoing Allogeneic Stem Cell Transplantation for High Risk Hematological Malignancies

Margaux Damge, Sabine Furst, MD, Bénédicte Devictor, Samia Harbi, MD, Joseph Ciccolini, Angela Granata, MD, Thomas Pagliardini, MD, Boris Calmels, Pharm.D., Claude Lemarie, Pharm.D., Luca Castagna, MD, Valerio Maisano, MD, Faezeh Legrand, MD, Anne-Marie Stoppa, MD, Reda Bouabdallah, Evelyne D'Incan, Norbert Vey, MD PhD, Christian Chabannon, MD PhD, Didier Blaise, MD PhD, Raynier Devillier, MD PhD

Blood (2019) 134 (Supplement_1): 4503.

https://doi.org/10.1182/blood-2019-125994

Published: 2019

Journal Articles

Comparison of Allogeneic Transplant Outcomes Using Conditioning with Different Dose of Busulfan for Children with Acute Myeloid Leukemia

Olesia V Paina, PhD, Zhemal Zarifovna Rakhmanova, Dr., Polina Valerievna Kozhokar, Dr., Anastasia S Frolova, Dr, Kirill Alexandrovich Ekushov, Dr., Luibov Tsvetkova, Tatiana A Bykova, MD PhD, Inna V Markova, Dr., Sergey N. Bondarenko, PhDMD, Ildar M Barkhatov, MD PhD, Aleksandr Alyanski, Elena Babenko, Ivan S Moiseev, MD PhD, Marina O Popova, MD PhD, Elena Vladimirovna Semenova, MD PhD, Ludmila S Zubarovskaya, MD PhD professor, Axel Zander, Boris Afanasyev

Blood (2019) 134 (Supplement_1): 4510.

https://doi.org/10.1182/blood-2019-128155

Published: 2019

Journal Articles

Adjusting BuCy 2 in Allogeneic Hematopoietic Stem Cell Transplantation to Improve Outcomes: Experience of a Limited-Resource Center in a Developing Country

Monica Magdalena Rivera Franco, MDMSc, Eucario Leon Rodriguez, MD

Blood (2019) 134 (Supplement_1): 4480.

https://doi.org/10.1182/blood-2019-122203

Published: 2019

Journal Articles

The Blood Microbiome Predicts Acute Graft-Versus-Host Disease after Stem Cell Transplantation

Lily Blair, PhD, Jonathan U. Peled, MD, Paul A Giardina, John B. Slingerland, BSc, Ann E. Slingerland, BSc, Desiree Hollemon, MPH, MSN, Carine Ho, Sivan Bercovici, Asim Ahmed, David K Hong, MD, Sergio A. Giralt, MD, Ying Taur, MD MPH, Marcel R.M. van den Brink, MD PhD, Kate A Markey, PhDMBBS,FRACP

Blood (2019) 134 (Supplement_1): 4513.

https://doi.org/10.1182/blood-2019-129272

Published: 2019

Journal Articles

Dual Epigenetic Agents Plus Rituximab-Gemcitabine-Oxaliplatin As a Salvage Treatment in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Changju Qu, PhD, Nana Ping, MD, PhD, Danqing Kong, MD, Fan Xia, MD, Depei Wu, MD PhD, Zhengming Jin, MD

Blood (2019) 134 (Supplement_1): 5338.

https://doi.org/10.1182/blood-2019-128111

Published: 2019

Journal Articles

Extranodal NK/T Cell Lymphoma Nasal Type: A Cohort Study from Latin America

Lidiane Inês Da Rosa, MD, Wellington Fernandes da Silva, MD, Andre Abdo, MD, Eduardo M Rego, MD PhD, Vanderson Rocha, MD PhD, Juliana Pereira, MD PhD

Blood (2019) 134 (Supplement_1): 5284.

https://doi.org/10.1182/blood-2019-126307

Published: 2019

Journal Articles

Pentotstatin/TBI Conditioning Is Well-Tolerated and Permits Engraftment of a Second Allogeneic Stem Cell Transplant Following Primary or Secondary Rejection of an Allogeneic Hematopoietic Stem Graft

Ani Gvajaia, MD, Amelia Langston, MD, Natia Esiashvil, MD, Michael Graiser, PhD, Kelly Valla, PharmD, Edmund K. Waller, PhDMD

Blood (2019) 134 (Supplement_1): 5657.

https://doi.org/10.1182/blood-2019-122467

Published: 2019

Journal Articles

Mucositis during Allogeneic Transplantation Determines Post-Transplant Serum Cyclosporin Levels

Joanne L C Tan, MBBS, Eric Wong, MD, Ashish Bajel, MBBS, FRACP, FRCPA, Radha Ramanan, MBBS, Andrew B M Lim, David Ritchie, MD PhD

Blood (2019) 134 (Supplement_1): 5662.

https://doi.org/10.1182/blood-2019-122363

Published: 2019

Journal Articles

Clinical Efficacy of L-Annamycin, a Liposomal Formulated Non-Cross-Resistant and Non-Cardiotoxic Anthracycline in Relapsed/Refractory AML Patients

Lidia Gil, MD PhD, Robert C. Shepard, MD, Sandra L Silberman, MD PhD, Ewa Maria Zak, MSc, Waldemar Priebe, PhD

Blood (2019) 134 (Supplement_1): 5147.

https://doi.org/10.1182/blood-2019-129268

Published: 2019

Journal Articles

Impact of Ethnicity on Toxicities Associated with Dose Escalating Methotrexate in Pediatric Patients with Acute Lymphoblastic Leukemia

Ashley Siryk, PharmD, Haley Grunwald, PharmD, Amanda Brahim, PharmD, Frank Gentile, PharmD, Faina Shenderov, PharmD, Carmen Ballestas, MD

Blood (2019) 134 (Supplement_1): 5074.

https://doi.org/10.1182/blood-2019-130268

Published: 2019

Journal Articles

Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (r/r AITL) North Asian Patients after Failure of First-Line Therapy: A Pooled Analysis of Two Pralatrexate Studies

Jun Zhu, MD, Ee-Min Yeoh, BSc, Yoshinobu Maeda, MD PhD

Blood (2019) 134 (Supplement_1): 5290.

https://doi.org/10.1182/blood-2019-124080

Published: 2019

Journal Articles

Isavuconazole Prophylaxis during Early Phases of Allogeneic HSC Transplantation Is Not Associated to an Increase Need of Cyclosporin-a Dose Modification

Alessandra Cupri, MD, Salvatore Leotta, MD, Uros Markovic, MD, Maria Grazia Camuglia, PhD, Giulio Antonio Milone, MD, Angelo Curto Pelle, MD, Valerio Leotta, MD, Mary Ann Di Giorgio, MD, Anna Bulla, MD, Di Marco Anna Lia, PhD, Gaetano Moschetti, MD, Giuseppe Milone, MD PhD

Blood (2019) 134 (Supplement_1): 3271.

https://doi.org/10.1182/blood-2019-127120

Published: 2019

Journal Articles

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Michael Low Cardenas, MD, Mehrdad Abedi, MD, Christina Romo, Carol M. Richman, MD, Megan Daly, MD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 3334.

https://doi.org/10.1182/blood-2019-130870

Published: 2019

Journal Articles

Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant

Karen Sweiss, PharmD, Bhaskar Vemu, PhD, Gregory Sampang Calip, PharmD,MPH,PhD, John P Galvin, MDMS,MPH, John G. Quigley, Nadim Mahmud, MBBS, PhD, Damiano Rondelli, MD, Jeremy Johnson, PharmD, PhD, Pritesh Patel, MB, ChB

Blood (2019) 134 (Supplement_1): 3310.

https://doi.org/10.1182/blood-2019-132216

Published: 2019

Journal Articles

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Locke J. Bryan, MD, Scott E. Smith, MD PhD, Pamela Allen, MDMSc, Carla Casulo, Brett Alan Palmer, BS, Reem Karmali, MD, Barbara Pro, MD, Denise M Scholtens, PhD, Hatice Savas, MD, Jayesh Mehta, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2019) 134 (Supplement_1): 4029.

https://doi.org/10.1182/blood-2019-123879

Published: 2019

Journal Articles

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Yehuda E. Deutsch, MD, Robert Wilkinson, PharmD, Amanda Brahim, PharmD, Stephanie Boisclair, MD, Jose Sandoval-Sus, MD, Annie Kuehnel, APRN, Terrence J Bradley, MD, Chetasi Talati, MD, Ellen Madarang, PharmD, Jillian Lykon, PharmD, Justin M. Watts, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Hugo F. Fernandez, MD

Blood (2019) 134 (Supplement_1): 3896.

https://doi.org/10.1182/blood-2019-129331

Published: 2019

NARROW

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b

Pharmacokinetic-Guided Busulfan Based Myeloablative Versus Fixed Dose Reduced Intensity Conditioning Regimen in Patients Older Than 55 Years Undergoing Allogeneic Stem Cell Transplantation for High Risk Hematological Malignancies

Comparison of Allogeneic Transplant Outcomes Using Conditioning with Different Dose of Busulfan for Children with Acute Myeloid Leukemia

Adjusting BuCy 2 in Allogeneic Hematopoietic Stem Cell Transplantation to Improve Outcomes: Experience of a Limited-Resource Center in a Developing Country

The Blood Microbiome Predicts Acute Graft-Versus-Host Disease after Stem Cell Transplantation

Dual Epigenetic Agents Plus Rituximab-Gemcitabine-Oxaliplatin As a Salvage Treatment in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients

Extranodal NK/T Cell Lymphoma Nasal Type: A Cohort Study from Latin America

Pentotstatin/TBI Conditioning Is Well-Tolerated and Permits Engraftment of a Second Allogeneic Stem Cell Transplant Following Primary or Secondary Rejection of an Allogeneic Hematopoietic Stem Graft

Mucositis during Allogeneic Transplantation Determines Post-Transplant Serum Cyclosporin Levels

Clinical Efficacy of L-Annamycin, a Liposomal Formulated Non-Cross-Resistant and Non-Cardiotoxic Anthracycline in Relapsed/Refractory AML Patients

Impact of Ethnicity on Toxicities Associated with Dose Escalating Methotrexate in Pediatric Patients with Acute Lymphoblastic Leukemia

Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (r/r AITL) North Asian Patients after Failure of First-Line Therapy: A Pooled Analysis of Two Pralatrexate Studies

Isavuconazole Prophylaxis during Early Phases of Allogeneic HSC Transplantation Is Not Associated to an Increase Need of Cyclosporin-a Dose Modification

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only